Tuesday, 25 January 2011

Investigators recruiting for study of gilenya capsules (fingolimod) in primary-progressive MS

From the MS Trust:

Investigators worldwide are recruiting 654 people with primary-progressive MS to study the safety and effectiveness of fingolimod capsules (Gilenya, Novartis Pharmaceuticals AG) versus inactive placebo.  Read full article here.